Welcome to Teva
Serving nearly 200 million people every day
Increasing access to medicines to enable better health is inherent to our business

- **1,150+** new generic medicine marketing authorizations
- **229** new marketing authorizations in low and middle-income countries

We collaborate with partners to get medicines to vulnerable populations

- **5** access to medicines programs launched*
- **533.7M** units (worth $699.6M) of medicines donated to patients in need

*5 in total (2021-2022) of our target of 8 by 2025
Environmental, Social & Governance (ESG)
To continue getting patients the medicines they need, we must do business responsibly

At Teva, we do this through ESG

**Environmental**
- Climate Action and Resilience
- Emissions, Effluents and Waste
- Responsible Use of Natural Resources

**Social**
- Minimizing the impact of our operations and products on the planet
- Advancing health and equity through our medicines and across our business
- Dedicating ourselves to quality, ethics and transparency

**Governance**
- Access to Health and Medicines
- Inclusion and Diversity
- Employee Engagement
- Business Ethics, Anti-bribery and Anti-corruption
- Responsible Supply Chain
- Quality Manufacturing and Patient Safety
- Data Privacy and Security

At Teva, we do this through ESG.
We’ve codified and managed ESG in FOUR WAYS

1. SETTING ambitious targets
2. ENHANCING reporting and disclosures
3. INTEGRATING into business
4. STRENGTHENING governance structure
<table>
<thead>
<tr>
<th>CLIMATE ACTION &amp; RESILIENCE</th>
<th>RESPONSIBLE USE OF NATURAL RESOURCES</th>
<th>EMISSIONS, EFFLUENTS AND WASTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 46%</td>
<td>• Increase energy efficiency by 10%</td>
<td>• Increase proportion of recycled and responsibly-sourced materials by 10%</td>
</tr>
<tr>
<td>• Reduce Scope 3 GHG by 25%</td>
<td>• Increase electricity from renewable sources to 50%</td>
<td>• Continue to minimize waste</td>
</tr>
<tr>
<td>• Targets validated by the Science Based Target initiative (SBTi) as being aligned with the 2015 Paris Climate Agreement</td>
<td>• Reduce total water withdrawal by 10% in water stressed areas</td>
<td>• Assess and minimize antimicrobial discharges from our operations and supply chain</td>
</tr>
</tbody>
</table>
We’re making progress

**Scope 1 & 2:**
Reduce GHG emissions by 25% by 2025 and 46% by 2030, as compared to 2019
- 24% achieved by end 2022

**Scope 3:**
Reduce GHG emissions by 25% by 2030, as compared to 2020
- 12% achieved by end 2022
Energy & process efficiencies

Renewable electricity procurement & generation

Network optimization
Thank You
Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

• our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;

• compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and any delay in our ability to obtain sufficient participation of plaintiffs for the nationwide settlement of our opioid-related litigation in the United States; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice (“DOJ”) criminal charges of Sherman Act violations; potential liability for Intellectual property right infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks and the impact of Environmental, Social and Governance (“ESG”) issues;

• other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the ongoing conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022 (“Annual Report”), including in the sections captioned “Risk Factors” and “Forward-looking statements.”

Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.